Nuvation Bio (NUVB) Other Non-Current Liabilities (2020 - 2025)
Nuvation Bio (NUVB) posted quarterly Other Non-Current Liabilities of $2.9 million for Q4 2025, up 39.55% year-over-year from $2.1 million in Q4 2024, and up 64.84% quarter-over-quarter from $1.7 million in Q3 2025.
Nuvation Bio (NUVB) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Other Non-Current Liabilities for 6 consecutive years, with $2.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 39.55% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (up 39.55% YoY), while the FY2025 annual figure was $2.9 million, up 39.55% from the prior year.
- Other Non-Current Liabilities rose to $2.9 million in Q4 2025 per NUVB's latest filing, from $1.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $15.1 million in Q2 2021 and bottomed at -$601000.0 in Q1 2021.
- Historically, Other Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $1.7 million in 2022.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 884.19% in 2022 and fell as far as 92.3% in 2022.
- Nuvation Bio's Other Non-Current Liabilities stood at $11.0 million in 2021, then plunged by 92.3% to $850000.0 in 2022, then slumped by 58.47% to $353000.0 in 2023, then jumped by 481.59% to $2.1 million in 2024, then surged by 39.55% to $2.9 million in 2025.
- Business Quant data shows NUVB's Other Non-Current Liabilities at $2.9 million in Q4 2025, $1.7 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.87 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 908,000.00 |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 353,000.00 |
| Sep 30, 2023 | 590,000.00 |
| Jun 30, 2023 | 972,000.00 |
| Mar 31, 2023 | 708,000.00 |
| Dec 31, 2022 | 850,000.00 |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 11.04 Mn |
| Sep 30, 2021 | 14.94 Mn |
| Jun 30, 2021 | 15.06 Mn |
| Mar 31, 2021 | -601,000.00 |